M
Malcolm R Ranson
Researcher at University of Manchester
Publications - 195
Citations - 15315
Malcolm R Ranson is an academic researcher from University of Manchester. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 57, co-authored 195 publications receiving 14150 citations. Previous affiliations of Malcolm R Ranson include Manchester Academic Health Science Centre & National Health Service.
Papers
More filters
Journal ArticleDOI
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi A. Jänne,James Chih-Hsin Yang,Dong Wan Kim,David Planchard,Yuichiro Ohe,Suresh S. Ramalingam,Myung-Ju Ahn,Sang We Kim,Wu Chou Su,Leora Horn,Daniel Haggstrom,Enriqueta Felip,Joo Hang Kim,Paul Frewer,Mireille Cantarini,Kathryn H. Brown,Paul A. Dickinson,Serban Ghiorghiu,Malcolm R Ranson +18 more
TL;DR: AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors.
Journal ArticleDOI
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Darren Cross,Susan Ashton,Serban Ghiorghiu,Cath Eberlein,Caroline A. Nebhan,Paula J. Spitzler,Jonathon P. Orme,M. Raymond V. Finlay,Richard A. Ward,Martine J. Mellor,Gareth D Hughes,Amar Rahi,Vivien Jacobs,Monica Red Brewer,Eiki Ichihara,Jing Sun,Hailing Jin,Peter Ballard,Katherine Al-Kadhimi,Rachel Rowlinson,Teresa Klinowska,Graham Richmond,Mireille Cantarini,Dong Wan Kim,Malcolm R Ranson,William Pao +25 more
TL;DR: A novel structurally distinct third-generation EGFR TKI that irreversibly and selectively targets both sensitizing and resistant T790M(+) mutant EGFR while harboring less activity toward wild-type EGFR is reported.
Journal ArticleDOI
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
Matthew G Krebs,Robert Sloane,Lynsey Priest,Lee Lancashire,Jian-Mei Hou,Alastair Greystoke,Timothy H Ward,Roberta Ferraldeschi,Andrew Hughes,Glen Clack,Malcolm R Ranson,Caroline Dive,Fiona H Blackhall +12 more
TL;DR: CTCs are detectable in patients with stage IV NSCLC and are a novel prognostic factor for this disease, and further validation is warranted before routine clinical application.
Journal ArticleDOI
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
Malcolm R Ranson,Lisa A. Hammond,David Ferry,Mark G. Kris,Andrew Tullo,Philip I. Murray,Vince Miller,Steven D. Averbuch,Judith Ochs,Charles A. Morris,A. Feyereislova,Helen Swaisland,Eric K. Rowinsky +12 more
TL;DR: ZD 1839 was well tolerated, with DLT observed at a dose well above that at which antitumor activity was seen, and Pharmacokinetic analysis confirmed that ZD1839 was suitable for administration as a once-daily oral tablet formulation.
Journal ArticleDOI
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin,Christine L. Hann,Edward B. Garon,Moacyr Ribeiro de Oliveira,Philip Bonomi,D. Ross Camidge,Quincy Chu,Giuseppe Giaccone,Divis Khaira,Suresh S. Ramalingam,Malcolm R Ranson,Caroline Dive,Evelyn McKeegan,Brenda Chyla,Barry L. Dowell,Arunava Chakravartty,Cathy E. Nolan,Niki Rudersdorf,Todd A. Busman,Mack Mabry,Andrew Krivoshik,Rod A. Humerickhouse,Geoffrey I. Shapiro,Leena Gandhi +23 more
TL;DR: Preclinical models support that navitoclax may enhance sensitivity of SCLC and other solid tumors to standard cytotoxics and Correlative analyses suggest several putative biomarkers of clinical benefit.